Navigating CML Treatment: A Patient-Centered Approach - Episode 2
Panelists discuss how mutation analysis should be considered when treatment fails to meet milestones or patients show loss of response to tyrosine kinase inhibitor (TKI) therapy, as this information helps determine whether to continue the current TKI or switch to an alternative agent based on the specific resistance profile.
Video content above is prompted by the following: